Eight people. Eight moments.
One platform that changes all of them.
Spryson is not a single-use diagnostic tool. It is a platform that sits at the intersection of every meaningful neurological moment — from the first worried conversation with a GP to the final data point in a Phase 3 clinical trial.
A 47-year-old woman has been experiencing persistent brain fog for eight months. She has seen three doctors. Every test has come back normal. She is told it is stress. A Spryson assessment identifies measurable deficits in cognitive processing speed and vestibular function — objective signals that something is genuinely wrong. For the first time, she has a number. A starting point. A direction.
A 52-year-old man's mother was diagnosed with Alzheimer's at 68. He is frightened. His GP has no tool to assess his risk objectively. A Spryson assessment establishes his neurological baseline — across all seven functional systems — so that every future measurement is compared against his own starting point, not a population average. He now has a longitudinal record. The earliest warning will not be missed.
A GP sees twelve patients a week with neurological complaints — dizziness, memory concerns, balance issues, cognitive changes. Until now, her only tools were questionnaires and referrals that take months. A Spryson assessment takes eight minutes and produces a structured clinical report with objective scores, risk signals, and suggested next steps. She can act now, not in six months.
A neurologist sees patients who have been waiting four months for an appointment. When they arrive, he has no objective baseline — only what they report and what he observes. Spryson gives him a structured neurological profile before the consultation begins. He can focus the appointment on interpretation and intervention rather than information gathering. His capacity effectively doubles.
A pharmaceutical company is running a Phase 3 trial for a Parkinson's disease-modifying therapy. They need patients in the early stage — before significant neuronal loss has occurred. Traditional recruitment takes years. Spryson's normative database identifies patients who match the trial profile from existing clinical data. Recruitment time compresses from years to months. The trial that changes Parkinson's treatment gets to market faster.
A 58-year-old executive spends $30,000 a year on his longevity program. His cardiovascular system has been comprehensively assessed. His metabolic markers are tracked quarterly. His genome has been sequenced. His brain has never been objectively measured. Spryson adds the one missing layer — a longitudinal neurological profile that shows where his brain is today, where it is heading, and what to do about it while there is still time to act.
A 64-year-old man is six weeks into vestibular rehabilitation after a fall. His therapist has no objective way to measure whether the treatment is working — only his self-report and clinical observation. Spryson remeasures his vestibular function scores against his pre-treatment baseline. The improvement is visible, measurable, and documentable. The therapist adjusts the protocol. The patient sees the evidence that the work is paying off.
A hospital network wants to build a neurological prevention program for patients over 60. They need a scalable, objective, reproducible assessment tool that works across multiple sites without specialist neurologists at every location. Spryson deploys across all sites in weeks. Every assessment feeds the same normative database. The data compounds. The program improves with every patient it sees.
